Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Apilimod dimesylate - OrphAI Therapeutics

Next Previous
Drug Profile

Apilimod dimesylate - OrphAI Therapeutics

Alternative Names: AIT-101; LAM 002A; LAM-002

Latest Information Update: 03 Nov 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator LAM Therapeutics
  • Developer OrphAI Therapeutics; Yale University
  • Class Antidementias; Antineoplastics; Antivirals; Hydrazines; Morpholines; Pyrimidines; Small molecules
  • Mechanism of Action Immunosuppressants; Interleukin 12 inhibitors; Interleukin 23 inhibitors; PIKFYVE protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Amyotrophic lateral sclerosis; Follicular lymphoma
  • New Molecular Entity No

Highest Development Phases

  • Suspended Amyotrophic lateral sclerosis
  • Discontinued COVID 2019 infections; Frontotemporal dementia; Non-Hodgkin's lymphoma

Most Recent Events

  • 03 Nov 2024 Discontinued - Phase-II for COVID-2019 infections in USA (PO) (OrphAI Therapeutics pipeline, September 2024)
  • 03 Nov 2024 Discontinued - Phase-II for Non-Hodgkin's lymphoma (Combination therapy, Second-line therapy or greater) in USA (PO) (OrphAI Therapeutics pipeline, September 2024)
  • 03 Nov 2024 Discontinued - Phase-II for Non-Hodgkin's lymphoma (Monotherapy, Second-line therapy or greater) in USA (PO) (OrphAI Therapeutics pipeline, September 2024)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top